Results 61 to 70 of about 21,604,258 (289)
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist [PDF]
Abstract The field of cancer immunotherapy has rapidly progressed in the past decade as several therapeutic modalities have entered into the clinic. One such immunotherapy that has shown promise in the treatment of cancer is the use of chimeric antigen receptor (CAR)-modified T lymphocytes.
Marcela V, Maus, Bruce L, Levine
openaire +2 more sources
Supplemental material, sj-pdf-1-aop-10.1177_10600280211026338 for Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma by Mary Kate Anderson, Annie Torosyan and Zachery Halford in Annals of
Annie Torosyan (11256987) +2 more
core +1 more source
Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley +1 more source
Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T) [PDF]
Chimeric antigen receptor (CAR) T cells represent one of the newest frontiers of cell therapy. Their application currently involves relapsed/refractory aggressive B cell lymphoma and leukemia as a standard of care, while several studies are exploring CAR-
Hohaus, Stefan +21 more
core +1 more source
Cell therapies typically rely on cold‐chain logistics and cryopreservation, limiting access and compromising cell quality. Here, a dual‐chamber device separates an oxygen‐supplying chamber from a hyaluronic acid cargo chamber, sustaining oxygen delivery for over 70 h and enabling ambient‐temperature shipment.
Daniel A. Domingo‐Lopez +9 more
wiley +1 more source
Advances in CAR-T therapy for central nervous system tumors
The application of chimeric antigen receptor T-cell therapy in central nervous system tumors has significantly advanced; however, challenges pertaining to the blood-brain barrier, immunosuppressive microenvironment, and antigenic heterogeneity continue ...
Delian Zhou, Xiaojian Zhu, Yi Xiao
doaj +1 more source
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Chimeric antigen receptor (CAR) T-cell therapy represents a new genetically engineered method of immunotherapy for cancer. The patient’s T-cells are modified to express a specific receptor that sticks to the tumor antigen.
Ovidiu Balacescu +8 more
core +1 more source
Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy
•Human herpesvirus-6 (HV-6) reactivation and myelitis have been reported in cases•Chimeric antigen receptor (CAR) T-cell therapy may also confer risk.•HHV-6 should be evaluated in encephalitis or myelitis after CAR T-cell therapy.
Mulanovich, Victor E. +22 more
core +1 more source
Bacteria‐Trained, MnO2‐Armored Dendritic Cells for Immunotherapy
MnO2‐armored, bacteria‐trained dendritic cells undergo tumor‐responsive mechanical and immunological transformation. The nanocoating masks immune ligands and maintains a mechanically stiff, quiescent state during circulation, while the tumor microenvironment removes the armor and restores cellular deformability and immune accessibility.
Zhao Guo +9 more
wiley +1 more source
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some ...
Erhao Zhang, Hanmei Xu
doaj +1 more source

